A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-181, a Monoclonal Antibody, as Monotherapy and in Combination With Another Anti-Cancer Therapy in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2017
At a glance
- Drugs ABBV 181 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 15 Nov 2017 Planned number of patients changed from 158 to 182.
- 17 Jul 2017 Protocol was amended to include changes in drug combination and change in treatment arms
- 17 Jul 2017 Planned End Date changed from 22 Jun 2022 to 18 Sep 2019.